Pfizer reported three consecutive quarters in 2025 where both revenues and earnings per share exceeded analysts’ expectations, driven by disciplined cost management and strong product execution. Between 2024 and 2025, the company reduced operating expenses by $5.6 billion through workforce optimization, streamlined R&D initiatives and tighter supply-chain controls. These measures contributed to a margin expansion of approximately 250 basis points year-over-year, underscoring Pfizer’s ability to deliver profitable growth even in a challenging macroeconomic environment.

During the J.P. Morgan Healthcare Conference, CEO Albert Bourla highlighted two major overhangs that weighed on Pfizer’s valuation: potential changes to Most-Favored-Nation (MFN) tariffs and lingering concerns over post-pandemic COVID product profitability. With bipartisan support in Washington and finalized MFN guidelines, Pfizer now expects a more predictable pricing framework for its international markets. Additionally, management has clarified the long-term margin contribution from its COVID portfolio, alleviating investor concerns about future earnings volatility.

Pfizer’s Phase 3 BREAKWATER trial in BRAF V600E-mutant metastatic colorectal cancer demonstrated a 64.4% confirmed objective response rate for the Braftovi plus cetuximab and FOLFIRI regimen, significantly outperforming the 39.2% response seen with standard-of-care therapy. These results supported the drug’s accelerated FDA approval in December 2024, with full approval pending verification of clinical benefit. Management projects peak annual sales for this indication could exceed $1.2 billion globally, based on prevalent mutation rates and historical uptake patterns in refractory colorectal cancer populations.